Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2026 05:00 ET | Source: Disco Pharmaceuticals GmbH

DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies

DISCO signs exclusive deal with Amgen to develop cancer therapies from its surfaceome platform; deal worth up to $618M plus royalties.
December 11, 2025 05:00 ET | Source: Disco Pharmaceuticals GmbH

DISCO Pharmaceuticals Appoints Mark Manfredi as CEO and Announces Final Close of €36 Million Seed Financing

DISCO Pharmaceuticals appoints biotech leader Mark Manfredi as CEO and raises €36M to advance surfaceome-targeted ADC therapies for hard-to-treat tumors